Filter documents Clear search

pdf icon

FSRH CEU Statement on Nexplanon® Insertion Site 15 January 2020

File size: 327kb | Date: 15 January 2020 | Clinical Statements - PDF

This CEU Statement provides guidance to healthcare professionals in response to a letter circulated by MSD (manufacturer of Nexplanon®) to healthcare professionals in the UK about updated guidance regarding the recommended Nexplanon® insertion site.

pdf icon

FSRH response to new study using a mathematical model to inform dose and regimen of exogenous hormones (April 2023)

File size: 347kb | Date: 13 April 2023 | Clinical Statements - PDF

A new mathematical model suggests that effective suppression of ovulation for contraception could be achieved using lower doses of progestogen and estrogen than those currently used in hormonal contraceptives. A paper published today in PLOS Computational Biology describes the model and its findings. The authors highlight that lower exposure to exogenous hormones could reduce associated health risks and side effects. The model could be used to inform dose and regimen of exogenous hormones to be investigated by future clinical trials seeking to find new options for safe, effective and acceptable contraception. Clinical trials would be required to investigate what outcomes, with such regimens, were found in practice.

pdf icon

FSRH CEU Statement: New manufacturer/MHRA advice regarding nomegestrol acetate – how does this affect prescribing of Zoely®? (April 2023)

File size: 497kb | Date: 13 April 2023 | Clinical Statements - PDF

Theramex, in agreement with the MHRA, has issued a direct healthcare professional communications (DHPC) letter relating to prescribing of Zoely®, a combined oral contraceptive containing estradiol in combination with 2.5mg of the progestogen nomegestrol acetate (NOMAC).

The guidance is a response to evidence indicating an association between use of preparations containing nomegestrol acetate at higher doses than in Zoely (3.75mg-5mg) and increased risk of intracranial meningioma.

There is not evidence relating directly to use of Zoely itself.

pdf icon

FSRH CEU Statement Response to Edelman 2022 (August 2022)

File size: 402kb | Date: 4 August 2022 | Clinical Statements - PDF

A new study (Edelman 2022) adds to the evidence around use of LNG-EC by those with higher weight/BMI but does not give a clear enough picture to inform any change in guidance.

pdf icon

FSRH CEU Statement: Response to Endler 2022 (July 2022)

File size: 357kb | Date: 6 July 2022 | Clinical Statements - PDF

A recently-published literature review considers the evidence around mechanism of action of levonorgestrel oral emergency contraception (LNG-EC). The findings support current FSRH guidance on emergency contraception, and are reassuring for those with ethical concerns about post-ovulation effects.

pdf icon

FSRH CEU Statement: Response to Heikinheimo 2022 (June 2022)

File size: 505kb | Date: 22 June 2022 | Clinical Statements - PDF

This FSRH Statement responses to a recently published cohort study, which used information from Finnish databases, assessed incidence of confirmed venous thromboembolic (VTE) events in 2018/19 amongst the roughly 300,000 Finnish people aged 15-49 who were using hormonal contraception (HC) in 2017 (identified from the prescribing database) and age-matched controls who were not using hormonal contraception.

pdf icon

FSRH CEU Resource: New one-handed, reloadable 52mg levonorgestrel-releasing intrauterine system

File size: 372kb | Date: 10 November 2021 | Clinical Statements - PDF

Benilexa® (Gedeon Richter) - a 52mg levonorgestrel-releasing intrauterine system (LNG-IUS) with a reloadable one-handed insertion device - is now available in the UK. Benilexa is licensed for 6 years of use for contraception. It is not licensed for endometrial protection as part of HRT. This FSRH CEU Resource provides a table which compares the product characteristics of LNG-IUS devices currently available in the UK, Benilexa®, Levosert®, Mirena®, Kyleena® and Jaydess®.